Related references
Note: Only part of the references are listed.Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
Juliette Lambert et al.
HAEMATOLOGICA (2019)
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
Diogo Gomes-Silva et al.
MOLECULAR THERAPY (2019)
Targeting PR1 in myeloid leukemia
Gheath Alatrash et al.
ONCOTARGET (2018)
Advances in treatment formulations for acute myeloid leukemia
Thomas Briot et al.
DRUG DISCOVERY TODAY (2018)
Advances in immunotherapy for acute myeloid leukemia
Amanda Przespolewski et al.
FUTURE ONCOLOGY (2018)
Improving combination cancer therapy: the CombiPlex((R)) development platform
Anthony W. Tolcher et al.
FUTURE ONCOLOGY (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
NK CellsMediateaCrucialGraft-versusLeukemia EffectinHaploidentical-HSCT to CureHigh-RiskAcuteLeukemia
Franco Locatelli et al.
TRENDS IN IMMUNOLOGY (2018)
The inducers of immunogenic cell death for tumor immunotherapy
Xiuying Li
TUMORI JOURNAL (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
Enasidenib for the treatment of acute myeloid leukemia
James Dugan et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
The inducers of immunogenic cell death for tumor immunotherapy
Xiuying Li
TUMORI JOURNAL (2018)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
Amir T. Fathi et al.
BLOOD (2018)
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
Arjan A. van de Loosdrecht et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Generation and evaluation of an FLT3 CAR-T cell therapy for the treatment of acute myeloid leukemia
Alice Bakker et al.
CANCER RESEARCH (2018)
The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia
David A. Sallman et al.
CANCER RESEARCH (2018)
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Peter G. Maslak et al.
BLOOD ADVANCES (2018)
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M. H. Qazilbash et al.
LEUKEMIA (2017)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
Polysaccharide-based nanoparticles for co-loading mitoxantrone and verapamil to overcome multidrug resistance in breast tumor
Yurui Xu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Recent developments in immunotherapy of acute myeloid leukemia
Felix S. Lichtenegger et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Liran I. Shlush et al.
NATURE (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mechanocellular models of epithelial morphogenesis
Alexander G. Fletcher et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2017)
CAR-T therapy for leukemia: progress and challenges
Xin Wang et al.
TRANSLATIONAL RESEARCH (2017)
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Abhishek D. Garg et al.
ONCOIMMUNOLOGY (2017)
Liposomal Formulations in Clinical Use: An Updated Review
Upendra Bulbake et al.
PHARMACEUTICS (2017)
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Andrew H. Wei et al.
BLOOD (2017)
Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine
Stephen Sze-Yuen Lam et al.
BLOOD REVIEWS (2017)
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Prithviraj Bose et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling
Fritz Aberger et al.
CELL COMMUNICATION AND SIGNALING (2017)
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen et al.
BLOOD (2016)
Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells
Abhijit Sarkar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2016)
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients
J. Fucikova et al.
BLOOD (2016)
Harnessing the immune system in acute myeloid leukaemia
Rebecca Austin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Vitamin E succinate-conjugated F68 micelles for mitoxantrone delivery in enhancing anticancer activity
Yuling Liu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance
Aleksandra Szulc et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Effect of quercetin and resveratrol co-incorporated in liposomes against inflammatory/oxidative response associated with skin cancer
Carla Caddeo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
PRCosomes: pretty reactive complexes formed in liposomes
Mohamed Wehbe et al.
JOURNAL OF DRUG TARGETING (2016)
Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes
Paul Tardi et al.
JOURNAL OF DRUG TARGETING (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
Jacalyn Rosenblatt et al.
Science Translational Medicine (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
Vinod A. Pullarkat et al.
CANCER DISCOVERY (2016)
Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study
Xiang-Yu Zhao et al.
ONCOIMMUNOLOGY (2016)
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The MCL-1 targeting effect of alvocidib potentiates the activity of cytarabine and mitoxantrone in a time-sequential regimen in AML
Wontak Kim et al.
Clinical Lymphoma Myeloma & Leukemia (2015)
The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia
Steven Knapper
HAEMATOLOGICA (2015)
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
Joshua F. Zeidner et al.
HAEMATOLOGICA (2015)
Anti-cancer evaluation of quercetin embedded PLA nanoparticles synthesized by emulsified nanoprecipitation
Sanjeev K. Pandey et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2015)
Immunogenic cell death
Abhishek D. Garg et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2015)
Liposomes as nanomedical devices
Giuseppina Bozzuto et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Andreas Wicki et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi et al.
LANCET ONCOLOGY (2015)
CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia
Hong Li et al.
MOLECULAR PHARMACEUTICS (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The odds of immunotherapy success
Matthew M. Gubin et al.
SCIENCE (2015)
Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia
Amy L. Paguirigan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia
Steven Knapper
HAEMATOLOGICA (2015)
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
Joshua F. Zeidner et al.
HAEMATOLOGICA (2015)
Combinatorial strategies for the induction of immunogenic cell death
Lucillia Bezu et al.
FRONTIERS IN IMMUNOLOGY (2015)
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Nestor R. Ramos et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Repair of spinal cord injury by inhibition of astrocyte growth and inflammatory factor synthesis through local delivery of flavopiridol in PLGA nanoparticles
Hao Ren et al.
BIOMATERIALS (2014)
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy
Jianliang Yang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia
Lene Myhren et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2014)
Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect
ChunLei Li et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
Quercetin conjugated superparamagnetic magnetite nanoparticles for in-vitro analysis of breast cancer cell lines for chemotherapy applications
S. Rajesh Kumar et al.
JOURNAL OF COLLOID AND INTERFACE SCIENCE (2014)
Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia
M-P Garcia-Cuellar et al.
LEUKEMIA (2014)
Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia
Kuan-Boone Tan et al.
NANOMEDICINE (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp et al.
ONCOIMMUNOLOGY (2014)
Hematopoietic Stem Cell Transplantation-50 Years of Evolution and Future Perspectives
Israel Henig et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2014)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Enhanced uptake and cytotoxity of folate-conjugated mitoxantrone-loaded micelles via receptor up-regulation by dexamethasone
Han Chen et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Acute myeloid leukaemia in adults
Felicetto Ferrara et al.
LANCET (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Amphiphilic dextran derivatives nanoparticles for the delivery of mitoxantrone
Huan Wang et al.
JOURNAL OF APPLIED POLYMER SCIENCE (2012)
Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid Leukemia
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Mitoxantrone-loaded zeolite beta nanoparticles: Preparation, physico-chemical characterization and biological evaluation
Stefan Grund et al.
JOURNAL OF COLLOID AND INTERFACE SCIENCE (2012)
Spectroscopic investigations of the molecular interaction of anticancer drug mitoxantrone with non-ionic surfactant micelles
Mirela Enache et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2012)
Mitoxantrone-Iron Oxide Biodistribution in Blood, Tumor, Spleen, and Liver-Magnetic Nanoparticles in Cancer Treatment
Manfred G. Krukemeyer et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Poly (D,L-lactic-co-glycolide) Nanoparticles for the Improved Therapeutic Efficacy of All-trans-retinoic Acid: A Study of Acute Myeloid Leukemia (AML) Cell Differentiation In Vitro
Aswathy Mary Simon et al.
Medicinal Chemistry (2012)
Surface Functionalization of Mesoporous Silica Nanoparticles Controls Loading and Release Behavior of Mitoxantrone
Amit Wani et al.
PHARMACEUTICAL RESEARCH (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Bone marrow-targeted liposomal carriers
Keitaro Sou et al.
EXPERT OPINION ON DRUG DELIVERY (2011)
Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model
Wei Yang et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2011)
Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes
Maria Coimbra et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Eric J. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Spectral Studies on the Molecular Interaction of Anticancer Drug Mitoxantrone with CTAB Micelles
Mirela Enache et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Cytarabine Dose for Acute Myeloid Leukemia
Bob Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment
Man-Yi Wong et al.
ANTI-CANCER DRUGS (2010)
Preparation, Characterization, and In Vivo Evaluation of Mitoxantrone-loaded, Folate-conjugated Albumin Nanoparticles
Liang-ke Zhang et al.
ARCHIVES OF PHARMACAL RESEARCH (2010)
Intensively Timed Combination Chemotherapy for the Induction of Adult Patients With Acute Myeloid Leukemia
Michael Rytting et al.
CANCER (2010)
The Binding of Flavopiridol to Blood Serum Albumin
Daniel Myatt et al.
CHIRALITY (2010)
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
William Blum et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome
Dushyant Verma et al.
LEUKEMIA & LYMPHOMA (2010)
β-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity
Alina Shapira et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2010)
Secondary acute myeloid leukemia - a single center experience
T. Szotkowski et al.
NEOPLASMA (2010)
Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia
Paul M. Armistead et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
Gerald Batist et al.
CLINICAL CANCER RESEARCH (2009)
Therapy-related myeloid neoplasms
Richard A. Larson
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
A novel liposomal formulation of flavopiridol
Xiaojuan Yang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
Paul Tardi et al.
LEUKEMIA RESEARCH (2009)
A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma
Qinghua Zhou et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2009)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Acute Myelogenous Leukemia in Older Adults
Heidi D. Klepin et al.
ONCOLOGIST (2009)
Copper ion-mediated liposomal encapsulation of mitoxantrone: The role of anions in drug loading, retention and release
ChunLei Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy
ChunLei Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2008)
Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone
ChunLei Li et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Pharmacokinetics and In Vivo Drug Release Rates in Liposomal Nanocarrier Development
Daryl C. Drummond et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Flavopiridol displays preclinical activity in acute lymphoblastic leukemia
Kelly M. Jackman et al.
PEDIATRIC BLOOD & CANCER (2008)
Deregulation of signaling pathways in acute myeloid leukemia
Claudia Scholl et al.
SEMINARS IN ONCOLOGY (2008)
Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety
B. Lowenberg
Hematology-American Society of Hematology Education Program (2008)
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
Fumihiko Ishikawa et al.
NATURE BIOTECHNOLOGY (2007)
Effect of cytarabine and decitabine in combination in human leukemic cell lines
Taichun Qin et al.
CLINICAL CANCER RESEARCH (2007)
The leukemic stem cell
Craig T. Jordan
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Targeting the Hedgehog pathway in cancer
Lee L. Rubin et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
Lawrence D. Mayer et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Liposomal quercetin efficiently suppresses growth of solid tumors in murine models
Zhi-ping Yuan et al.
CLINICAL CANCER RESEARCH (2006)
Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases
B Lu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity
N Dos Santos et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
EJ Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preparation, characterization, and stability of liposome-based formulations of mitoxantrone
S Ugwu et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2005)
Clinical pharmacokinetics of cytarabine formulations
A Hamada et al.
CLINICAL PHARMACOKINETICS (2002)
The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase
A Kaiser et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2001)
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies
AM Senderowicz
LEUKEMIA (2001)
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status
LR Kelland
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Share Paper
